AbbVie inks Humira patent deal No. 7, delaying Pfizer’s US biosim launch until late 2023 FiercePharma
Following a handful of deals for other biosimilar drugmakers, Pfizer decided to settle its Humira patent fight with AbbVie and agreed on a Nov. 20, 2023, U.S. …